NewAmsterdam Pharma posts BROADWAY trial presentation on obicetrapib kidney outcomes

Reuters

Yesterday

NewAmsterdam Pharma posts BROADWAY trial presentation on obicetrapib kidney outcomes

NewAmsterdam Pharma published a medical research presentation on CETP inhibition with obicetrapib and kidney function outcomes in patients at high cardiovascular risk, reporting results from the BROADWAY trial and a post hoc pooled analysis with the BROOKLYN trial.
The pooled analysis included 2,832 randomized participants with at least 1 postbaseline eGFR assessment and 1,897 participants with at least 1 postbaseline UACR measurement.
Annualized eGFR decline was -0.41 mL/min/1.73 m2 per year with obicetrapib versus -1.08 mL/min/1.73 m2 per year with placebo, with a reported difference of 0.67 and nominal P=0.02.
Composite renal events were reported in 1.9% of participants on obicetrapib versus 3.0% on placebo.
The presentation reported no significant difference between groups in annualized changes in UACR.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NewAmsterdam Pharma Company NV published the original content used to generate this news brief on March 24, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2622505019"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2622505019\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2622505019?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-25 06:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622505019","market":"nz","top_or_hot":-1,"title":"NewAmsterdam Pharma posts BROADWAY trial presentation on obicetrapib kidney outcomes","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NewAmsterdam Pharma posts BROADWAY trial presentation on obicetrapib kidney outcomes\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          NewAmsterdam Pharma published a medical research presentation on CETP inhibition with obicetrapib and kidney function outcomes in patients at high cardiovascular risk, reporting results from the BROADWAY trial and a post hoc pooled analysis with the BROOKLYN trial.\n        </li>\n<li>\n          The pooled analysis included 2,832 randomized participants with at least 1 postbaseline eGFR assessment and 1,897 participants with at least 1 postbaseline UACR measurement.\n        </li>\n<li>\n          Annualized eGFR decline was -0.41 mL/min/1.73 m2 per year with obicetrapib versus -1.08 mL/min/1.73 m2 per year with placebo, with a reported difference of 0.67 and nominal P=0.02.\n        </li>\n<li>\n          Composite renal events were reported in 1.9% of participants on obicetrapib versus 3.0% on placebo.\n        </li>\n<li>\n          The presentation reported no significant difference between groups in annualized changes in UACR.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NewAmsterdam Pharma Company NV published the original content used to generate this news brief on March 24, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NewAmsterdam Pharma posts BROADWAY trial presentation on obicetrapib kidney outcomes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNewAmsterdam Pharma posts BROADWAY trial presentation on obicetrapib kidney outcomes\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-25 06:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NewAmsterdam Pharma posts BROADWAY trial presentation on obicetrapib kidney outcomes\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          NewAmsterdam Pharma published a medical research presentation on CETP inhibition with obicetrapib and kidney function outcomes in patients at high cardiovascular risk, reporting results from the BROADWAY trial and a post hoc pooled analysis with the BROOKLYN trial.\n        </li>\n<li>\n          The pooled analysis included 2,832 randomized participants with at least 1 postbaseline eGFR assessment and 1,897 participants with at least 1 postbaseline UACR measurement.\n        </li>\n<li>\n          Annualized eGFR decline was -0.41 mL/min/1.73 m2 per year with obicetrapib versus -1.08 mL/min/1.73 m2 per year with placebo, with a reported difference of 0.67 and nominal P=0.02.\n        </li>\n<li>\n          Composite renal events were reported in 1.9% of participants on obicetrapib versus 3.0% on placebo.\n        </li>\n<li>\n          The presentation reported no significant difference between groups in annualized changes in UACR.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NewAmsterdam Pharma Company NV published the original content used to generate this news brief on March 24, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NAMS","symbol_name":"NEWAMSTERDAM PHARMA CO NV","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL5nzm7R:1","article_id":"2622505019","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622505019","pubTimestamp":1774390951,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"NewAmsterdam Pharma published a medical research presentation on CETP inhibition with obicetrapib and kidney function outcomes in patients at high cardiovascular risk, reporting results from the BROADWAY trial and a post hoc pooled analysis with the BROOKLYN trial.The pooled analysis included 2,832 randomized participants with at least 1 postbaseline eGFR assessment and 1,897 participants with at least 1 postbaseline UACR measurement.Annualized eGFR decline was -0.41 mL/min/1.73 m2 per year with obicetrapib versus -1.08 mL/min/1.73 m2 per year with placebo, with a reported difference of 0.67 and nominal P=0.02.Composite renal events were reported in 1.9% of participants on obicetrapib versus 3.0% on placebo.The presentation reported no significant difference between groups in annualized changes in UACR.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NAMS":"NEWAMSTERDAM PHARMA CO NV","BK4139":"生物科技"},"translate_title":"NewAmsterdam Pharma发布关于obicetrapib肾脏结果的百老汇试验演示","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NAMS":0.9},"content_text":"NewAmsterdam Pharma posts BROADWAY trial presentation on obicetrapib kidney outcomes\n    \n\n\n          NewAmsterdam Pharma published a medical research presentation on CETP inhibition with obicetrapib and kidney function outcomes in patients at high cardiovascular risk, reporting results from the BROADWAY trial and a post hoc pooled analysis with the BROOKLYN trial.\n        \n\n          The pooled analysis included 2,832 randomized participants with at least 1 postbaseline eGFR assessment and 1,897 participants with at least 1 postbaseline UACR measurement.\n        \n\n          Annualized eGFR decline was -0.41 mL/min/1.73 m2 per year with obicetrapib versus -1.08 mL/min/1.73 m2 per year with placebo, with a reported difference of 0.67 and nominal P=0.02.\n        \n\n          Composite renal events were reported in 1.9% of participants on obicetrapib versus 3.0% on placebo.\n        \n\n          The presentation reported no significant difference between groups in annualized changes in UACR.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NewAmsterdam Pharma Company NV published the original content used to generate this news brief on March 24, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}